Archive for Care for adults
If you’ve ever donated blood or platelets, there’s a reasonable chance that your donation went to help a cancer patient. That’s because cancer and certain treatments can damage blood cells, which means some patients may need transfusions of one or more types of blood components:
Cancer treatments, especially chemotherapy, can make eating well and enjoying food a challenge for many patients. Food may start to taste strange, appetite may diminish, and other symptoms, such as fatigue, bowel changes, nausea, and mouth sores, may make finding nutritious, delicious foods difficult.
“During chemotherapy, it’s very common for patients to not feel like eating, for appetite to be low, or the taste of food to be off,” says Dana-Farber nutritionist Stacy Kennedy, MPH, RD, who stresses the importance of maintaining a healthy diet to manage symptoms. In the video below, Kennedy explains how to combat symptoms by incorporating tart or sour flavors, eating small and frequent meals, and staying hydrated:
Chemotherapy and radiation are often prescribed because they are both very effective at destroying cells that grow rapidly, such as cancer cells. Unfortunately, they can also harm healthy cells that grow quickly, such as the cells lining the inside of your mouth. Patients undergoing chemo or radiation treatment often report mouth problems, such as sores, dry mouth, or infections, because the treatments make it difficult for the mouth to heal itself and fend off germs.
To help prevent or minimize mouth problems, consider these tips:
For about 70 years, the standard treatment for patients with advanced prostate cancer was drugs that blocked male hormones feeding the tumor. If that stopped working and the disease progressed, oncologists turned to chemotherapy to kill the cancer cells.
This timetable is about to change. Results of a clinical trial led by a Dana-Farber researcher revealed that such patients lived longer if started on both a hormone blocker and a chemotherapy drug at the same time. The government-sponsored trial found that 69 percent of men receiving both treatments were alive at three years, compared with 52.5 percent of men who initially got just the hormone blocker. The advantage was so striking – especially for patients with greater degrees of cancer spread – that the National Cancer Institute publicized the findings ahead of schedule to alert doctors and patients.
“The results of this study are practice-changing for some patients,” says Christopher Sweeney, MBBS, clinical director of Dana-Farber’s Lank Center for Genitourinary Cancer, who headed the trial. We asked him to explain:
Approximately 10,000-11,000 women in the U.S. are diagnosed with cervical cancer every year. But with women having regular cervical cancer screenings, incidence and death rates from the disease have decreased by at least 80 percent in the U.S.
“Cervical cancer in the U.S. has become less of a frequently diagnosed cancer because of the institution of the Pap smear,” says Ursula Matulonis, MD, medical director of Gynecologic Oncology at the Susan F. Smith Center for Women’s Cancers at Dana-Farber.
As January marks Cervical Cancer Awareness Month, here are five important questions about cervical cancer screening:
Ann LaCasce, MD, a medical oncologist in the Dana-Farber/Brigham and Women’s Cancer Center Adult Lymphoma Program, answered a variety of questions about Hodgkin and non-Hodgkin lymphoma during a live web chat hosted by Dana-Farber last month.